In his regular column, Dr James Le Fanu answers your questions. This week, a reader asks whether her overactive bladder ...

Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Habitually getting up to pee in the middle of the night can impact sleep quality. Here's how to cut down on these nighty ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

I am Greek and have thalassemia minor. In general, my red blood cells are much smaller than typical ones, and my iron content ...

ONO-4915 is under clinical development by Ono Pharmaceutical and currently in Phase I for Autoimmune Disorders.

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...